Friday, June 2, 2023, Chicago, Illinois, 11:45 AM – 12:45 PM Central Time (12:45 PM – 1:45 PM Eastern Time)

Lunch with the Investigators: Gastroesophageal Cancers

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
11:30 AM – 11:45 AM — Registration and Lunch
11:45 AM – 12:45 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)

This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
Yelena Y Janjigian, MD
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Manish A Shah, MD
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Professor of Gastrointestinal Oncology
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

Harry H Yoon, MD, MHS
Professor of Oncology
Enterprise-Wide Vice-Chair
Gastrointestinal Cancer Disease Group
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Lilly, and Novartis.
Program Schedule — Central Time
11:30 AM – 11:45 AM — Registration and Lunch Buffet
11:45 AM – 12:45 PM — Educational Meeting

MODULE 1: Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers

  • Effect of primary tumor location, biomarker status and other clinical factors on prognosis and selection of therapy for patients with GE cancers
  • Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable microsatellite instability-high gastric or gastroesophageal junction (GEJ) adenocarcinoma
  • Available data with, appropriate patient selection for and optimal duration of treatment with adjuvant nivolumab for resected esophageal or GEJ cancer
  • Published data sets, including from the CheckMate 649, KEYNOTE-859, CheckMate 648 and KEYNOTE-590 trials, demonstrating the efficacy and safety of first-line nivolumab- and pembrolizumab-containing regimens for advanced gastric, GEJ and esophageal cancer
  • Mechanism of action of tislelizumab; similarities and differences with commercially available anti-PD-1/PD-L1 antibodies
  • Published and emerging findings from Phase III studies, such as RATIONALE-305, 306 and 302, evaluating tislelizumab-based therapy for gastric, GEJ or esophageal cancer; potential role in routine practice
  • Other available clinical research findings with immune checkpoint inhibitors for the management of HER2-negative GE cancers

MODULE 2: Optimal Management of HER2-Positive GE Cancers

  • Available data from the Phase III KEYNOTE-811 trial evaluating the addition of pembrolizumab to chemotherapy and trastuzumab for previously untreated, HER2 positive advanced gastric or GEJ adenocarcinoma
  • Available efficacy and safety data from the DESTINY-Gastric01 and DESTINY-Gastric02 trials evaluating trastuzumab deruxtecan (T-DXd) for Asian and Western patients, respectively, with previously treated advanced gastric or GEJ cancer
  • Incidence, evaluation and management of interstitial lung disease and other toxicities associated with T-DXd for HER2-positive GE cancers
  • Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab
  • Recently presented findings with zanidatamab/chemotherapy as first-line therapy for advanced HER2-positive GE adenocarcinoma; ongoing evaluation of up-front zanidatamab and chemotherapy with or without tislelizumab in the Phase III HERIZON-GEA-01 trial
  • Other agents and strategies under investigation for HER2-positive disease

MODULE 3: Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches

  • Optimal integration of ramucirumab into the management of previously treated advanced gastric or GEJ cancer
  • Ongoing investigation of novel ramucirumab-containing combination regimens
  • Biological rationale for targeting claudin 18.2 in GE cancers; mechanism of action of zolbetuximab
  • Design, eligibility criteria and available results from the Phase III SPOTLIGHT and GLOW trials evaluating zolbetuximab with chemotherapy as first-line therapy for advanced gastric or GEJ adenocarcinoma
  • Potential clinical role of zolbetuximab and implications for biomarker assessment
  • Mechanism of action of bemarituzumab; available efficacy and safety data with first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Mechanistic rationale for, published data with and ongoing evaluation of longitudinal assessment of circulating tumor DNA to monitor for recurrence and inform therapeutic decision-making after potentially curative treatment
  • Available evidence with and ongoing evaluation of other promising agents and strategies for advanced GE cancers

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published and emerging research data with anti-PD-1/PD-L1 antibodies alone or with other systemic therapies for gastric, GEJ and esophageal cancer.
  • Optimally incorporate available agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
  • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal or GEJ cancer who have residual pathologic disease after neoadjuvant chemoradiation therapy.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer.
  • Evaluate the biologic rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess data with novel strategies directed at this potential biomarker.
  • Recognize common and rare side effects associated with approved and investigational agents for patients with gastroesophageal cancers, and apply this information to develop appropriate supportive management plans.
  • Review available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JanjigianAdvisory Committee and Consulting Agreements: AbbVie Inc, AmerisourceBergen, Arcus Biosciences, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Geneos Therapeutics, GSK, Guardant Health, Imugene, Lilly, Lynx Health LLC, Merck, Merck Serono, Mersana Therapeutics Inc, Michael J Hennessy Associates Inc, Pfizer Inc, Rgenix, Seagen Inc, Silverback Therapeutics, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Transcenta; Ownership – Private (Nonrelevant): Rgenix; Nonrelevant Financial Relationship: Clinical Care Options, Cycle for Survival, Fred’s Team, Imedex, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, US Department of Defense. Dr ShahContracted Research: Bristol Myers Squibb, Merck, Oncolys BioPharma. Dr YoonAdvisory Committee: ALX Oncology, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Elevation Oncology, MacroGenics Inc, Merck, Novartis, OncXerna Therapeutics, Zymeworks Inc; Consulting Agreements: Amgen Inc, Merck; Contracted Research: Amgen Inc, BeiGene Ltd, Bristol Myers Squibb, CARsgen Therapeutics, MacroGenics Inc, Merck; Travel: BeiGene Ltd.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Lilly, and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

​ ​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 11:15 AM Central Time on Friday, June 2. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.


Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.